dandan zhang United States

MNC pharmaceuticals company
Website:
Amgen.com
Partnering Objectives
Headquartner in China
AMGEN
senior associate scientist 

Dr. Alex Zhang United States

Cross border life science accelerator and angel investor based in San Francisco Bay Area and Wuxi, China.
Company Size (Fulltime employees)
Please specify your partnering goal
Greater China rights
Headquartner in China
Hanhai Biolabs, Inc.
CEO 
Functionality

Xu Zhang China

Partnering Objectives
Tianjin Medical University
Professor 

Wei Zhang China

Illumina is a provider of Next Generation Sequencing technology
Website:
www.illumina.com
Partnering Objectives
Headquartner in China
illumina
senior clinical specialist 

Dr. Kai Zhang United States

diagnostics
Website:
www.qiagen.com
Company Size (Fulltime employees)
Please specify your partnering goal
CDx partnership
Headquartner in China
Biotech/Pharma Category
QIAGEN
PM 
Functionality

Han Zhang China

China based company with focusing on psychiatry.
Website:
WWW.Foncoo.com
Partnering Objectives
Headquartner in China
Biotech/Pharma Category
Shenzhen Foncoo Pharmaceutical
Business Development Manager 

Dr. Jack Zhao United States

Pharmaceutical
Website:
www.JNJ.com
Company Size (Fulltime employees)
Please specify your partnering goal
Therapeutic
Headquartner in China
JNJ
Principal 

Ms. Linda Zhao China

Founded in 1970, Jiangsu Hengrui Medicine Co., Ltd. (JHM) is the largest publicly listed and a leading biopharma based in China with 24,700 employees devoted to empowering healthier lives through research. With over $3.3 billion in revenue in 2019, JHM has 6 new molecular entities approved in China as well as 30+ programs in clinical development in China, US, and Australia across oncology, anesthesiology & analgesics, autoimmune, and metabolic & cardiovascular therapeutic areas. Driven by internal R&D and global licensing and collaboration, JHM is committed to bring high quality products to patients.
Company Size (Fulltime employees)
Year of foundation
50 years
Partnering Objectives
Please specify your partnering goal
In-licensing clinical stage assets for China market; out-licensing ex-China rights of Hengrui assets
Headquartner in China
Assets Information 1
Please see the link below for our pipeline. Most of our assets are out-licensing candidates|https://www.hengruius.com/pipeline.html||China, US and global (please check with us for detailed info)
Jiangsu Hengrui Medicine Co.,Ltd.
Head, US BD Team 
Functionality

Ping Zhao China

CStone Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing innovative immuno-oncology and precision medicines to address the unmet medical needs of cancer patients in China and worldwide. Established in 2015, CStone has assembled a world-class management team with extensive experience in innovative drug development, clinical research, and commercialization. The company has built an oncology-focused pipeline of 15 drug candidates with a strategic emphasis on immuno-oncology combination therapies. Currently, 5 late-stage candidates are at pivotal trials. With an experienced team, a rich pipeline, a robust clinical development-driven business model and substantial funding, CStone's vision is to become globally recognized as a leading Chinese biopharmaceutical company by bringing innovative oncology therapies to cancer patients worldwide.
Partnering Objectives
Headquartner in China
CStone
Greater China General Manager and Head of Commercial Operations 

Adam Zhao

Anlong Fund Anlong Bio
Founding Partner CEO